HRP

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Retrieved on: 
Saturday, March 16, 2024
Diagnosis, Ovarian cancer, MIRV, Mutation, Health, BRCA, Science, Disease, Partnership, Patient, Education, Glomus tumor, Roche, Biomarker, Neoplasm, Research, Cancer, EOC, Recombinant DNA, Woman, HRP, PARP, TTD, Fibroadenoma, HRD, Mirvetuximab soravtansine, BRCA2, Recurrence, LH, BRCA1, ADP, Pharmaceutical industry

BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).

Key Points: 
  • The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).
  • Labcorp researchers conducted two studies to generate further evidence of the value of comprehensive genomic profiling to drive guideline-compliant testing that enables increased patient access to targeted therapies for improved outcomes.
  • When combined, the results of BRCA and HRD testing can determine which patients are most likely to benefit from treatment with poly-ADP ribose polymerase (PARP) inhibitors.
  • "This research emphasizes the power of comprehensive biomarker testing in advancing the treatment of ovarian cancer.

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
Tuesday, January 30, 2024
SAN, Breast, University, International, MD Anderson Cancer Center, FACMG, FDA, VAF, Bone marrow, SVS, Cytogenetics, Genome, LRS, OGM, University of Toronto, TNBC, Pressure, Biomarker, PARP, Quality control, Karyotype, HRD, Saint John Regional Hospital, T-ALL, CRISPR, Curie Institute, Triple-negative breast cancer, In situ hybridization, FISH, Frog, Genomics, Hospital, HRP, Patient, Marfan syndrome, Fluorescence, NIST, DSM-IV codes, Doctor of Philosophy, Cancer, Multiple myeloma, Workflow, Gene editing, Research, KT, Cell, Down syndrome, NGS, Vaccine

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”

Growth Propels a Company Name Change and New Brand Identity for HR Pharmaceuticals, Inc.

Retrieved on: 
Thursday, February 1, 2024
Growth, HRP, HR, Health, Urology, Nursing

YORK, Pa., Feb. 1, 2024 /PRNewswire/ -- Effective today, HR Pharmaceuticals, Inc. (HRP), a recognized name in healthcare consumables, will become HR HealthCare and launch a new company identity.  

Key Points: 
  • YORK, Pa., Feb. 1, 2024 /PRNewswire/ -- Effective today, HR Pharmaceuticals, Inc. (HRP), a recognized name in healthcare consumables, will become HR HealthCare and launch a new company identity.
  • HR HealthCare better embodies who the organization is today, the products and services provided, and the customers served.
  • "The transformation to HR HealthCare is rooted in bringing clarity to our partners and customers, accelerating growth, and supporting our organizational purpose of Positively Impacting People's Lives."
  • Visit hrhealthcare.com to learn more about HR HealthCare, the new brand identity, and its products.

If you or your property were impacted by the demolition of the smokestack at the former Crawford Coal Plant in Chicago's Little Village neighborhood in April 2020, you may be entitled to a cash payment

Retrieved on: 
Thursday, January 11, 2024
Notice, Kedzie Avenue, Counsel, Objection, Multimedia, HRP, Lawyer, The Honourable, Class, Settlement, Ogden Avenue, Summons, Comment, Exclusion, Cermak Road, Court, Claim, Controlled Demolition, Inc., Personal injury, Exercise, Insurance

COSTA MESA, Calif., Jan. 11, 2024 /PRNewswire/ -- Simpluris Inc. announces that a proposed settlement has been reached in a class action lawsuit claiming that Hilco Redevelopment, LLC, HRE Crawford, LLC, and HRP Exchange 55, LLC (collectively, "Hilco"), MCM Management Corp., Controlled Demolition, Inc., and Marine Technology Solutions LLC ("Defendants") acted improperly and caused damage when they demolished a smokestack on April 11, 2020, at the former Crawford Coal Plant, which was located at 3501 S. Pulaski Rd., Chicago, IL 60623. The settlement doesn't decide who is right, but rather is a compromise to end the lawsuit and avoid the uncertainties and costs associated with a trial.

Key Points: 
  • More information about the class and the settlement is available at www.LittleVillageSmokestack.com .
  • If the Court approves the settlement, Class Members who submit valid claims will receive a cash payment from the Settlement Fund.
  • You just need to complete and verify a short and simple Claim Form, which is available at www.LittleVillageSmokeStack.com .
  • If your property was damaged and you also qualify for a personal injury claim, you may select both options.

Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment

Retrieved on: 
Tuesday, December 5, 2023
Patient, Immunotherapy, Science, Rated R, Neoplasm, Survival, Immune system, Ovarian cancer, Principal, Research, Lung cancer, Paper, DNA, MD, Doctor of Philosophy, HRP, CPI, Randomized controlled trial, University, PARP, TMB, RFS, DNA repair, Ovary, Biomarker, Sequence, Cell, Meta-analysis, Research institute, Pharmaceutical industry

It reviews the potential limitations of certain immunotherapies designed without explicit consideration of clonal neoantigens.

Key Points: 
  • It reviews the potential limitations of certain immunotherapies designed without explicit consideration of clonal neoantigens.
  • This may also explain why clonal neoantigen targeting immunotherapies like Gradalis’ Vigil have shown longer-term overall survival benefits in a randomized controlled trial of patients with solid tumors.
  • Clonal mutations expressed on the cancer surface provide a distinguishing difference between cancer cells and normal non-cancer cells.
  • Emerging research shows that targeting clonal mutations may be critical in achieving a durable clinical benefit,” stated John Nemunaitis, MD, Chief Scientific Officer of Gradalis and co-author of the paper.

HR Pharmaceuticals, Inc. receives exclusive commercialization rights to Poiesis Medical's Dual Balloon Catheter technology in North America

Retrieved on: 
Thursday, December 28, 2023
Quality of life, MEDLINE, Commercial, Agreement, McKesson Corporation, Cardinal Health, Health, HRP, Duette, Florida, Catheter, Patient, Owens & Minor, Medical device

YORK, Pa., Dec. 28, 2023 /PRNewswire/ -- Today, HR Pharmaceuticals, Inc. (HRP) announced that they have entered into an Exclusive Commercial Agreement with Poiesis Medical LLC, under which HRP will license Poiesis's Dual Balloon Catheter (Duette™).

Key Points: 
  • YORK, Pa., Dec. 28, 2023 /PRNewswire/ -- Today, HR Pharmaceuticals, Inc. (HRP) announced that they have entered into an Exclusive Commercial Agreement with Poiesis Medical LLC, under which HRP will license Poiesis's Dual Balloon Catheter (Duette™).
  • Under the terms of the agreement, HRP will have exclusive commercialization rights in North America.
  • "The Dual Balloon Catheter has demonstrated significant benefits compared to traditional Foley catheters, leading to better patient outcomes.
  • HRP will begin processing North American orders for the Duette Dual Balloon Catheters starting January 2, 2024.

Hilco Global Warms the Winter by Providing Coats to Asylum Seekers and the Homeless

Retrieved on: 
Wednesday, December 20, 2023
Hilco Global, Hope, City, Marc, HRP, Clothing, Social responsibility

CHICAGO, Dec. 20, 2023 /PRNewswire/ -- Hilco Global, a prominent B2B financial services company is committed to giving back to communities where it does business by donating time, money and in-kind goods. "Hilco Helps Warm the Winter" initiative is designed to deliver assistance to local communities in need by providing basic cold-weather essentials including brand new winter coats, hats, gloves, scarves, etc. As the winter season unfolds, Hilco Global recognizes the heightened vulnerability of our neighboring communities, including the thousands of asylum seekers that have been flooding cold weather communities like Chicago, Boston, Philadelphia, etc.

Key Points: 
  • "Hilco Helps Warm the Winter" initiative is designed to deliver assistance to local communities in need by providing basic cold-weather essentials including brand new winter coats, hats, gloves, scarves, etc.
  • As the winter season unfolds, Hilco Global recognizes the heightened vulnerability of our neighboring communities, including the thousands of asylum seekers that have been flooding cold weather communities like Chicago, Boston, Philadelphia, etc.
  • This year, Hilco Global joined forces with the Marc and Jeanne Malnati Family Foundation to donate coats to offer warmth and comfort to asylum seekers facing the challenges of winter without adequate resources.
  • Hilco Redevelopment Partners (HRP), an operating company of Hilco Global, is also donating over 3000 coats in cities across the US.

Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas

Retrieved on: 
Thursday, November 16, 2023
New product development, Research, Immune system, HRP, TILS, Cancer, Patient, PARP, VITAL, Ovarian cancer, MD, Trial of the century, Survival, Neoplasm, Research institute, Pharmaceutical industry, Vaccine, Vigil

These patients face an acutely high unmet medical need due to the removal of PARP inhibitor therapies in 2022.

Key Points: 
  • These patients face an acutely high unmet medical need due to the removal of PARP inhibitor therapies in 2022.
  • The study is designed as a pivotal trial to confirm the positive survival results seen in ovarian cancer patients with the HRP profile tumors in Gradalis’ earlier VITAL study in frontline maintenance therapy.
  • Clonal neoantigens are tumor initiating mutations, and research by others has shown that the targeting of clonal neoantigens predicts survival in cancer patients.
  • “Following the extensive review of several drug development opportunities, CPRIT was impressed with Gradalis' Vigil product activity and clinical benefit results.

Hilco Redevelopment Partners Shares Thanksgiving Turkeys with Communities Across the Country

Retrieved on: 
Tuesday, November 21, 2023
Seaport District, HRP, House, Crawford, Potomac River, LEED, Volunteering, Tunnel, Boston, City

CHICAGO, Nov. 21, 2023 /PRNewswire/ -- In celebration of the Thanksgiving season, Hilco Redevelopment Partners (HRP) has completed its annual Turkey Drive initiative which aims to spread holiday spirit and gratitude in the communities surrounding HRP redevelopment projects. HRP redevelops complex industrial properties in major U.S. cities through a holistic approach that prioritizes environmental, economic, and community sustainability.

Key Points: 
  • Leader in Sustainable Redevelopment Joins Community Partners to Donate and Distribute Turkeys in Cities Across the U.S.
  • CHICAGO, Nov. 21, 2023 /PRNewswire/ -- In celebration of the Thanksgiving season, Hilco Redevelopment Partners (HRP) has completed its annual Turkey Drive initiative which aims to spread holiday spirit and gratitude in the communities surrounding HRP redevelopment projects.
  • HRP redevelops complex industrial properties in major U.S. cities through a holistic approach that prioritizes environmental, economic, and community sustainability.
  • Over the course of 10 days, HRP volunteers distributed over 2,500 turkeys to families in Chicago, Philadelphia, Boston, and Alexandria, Virginia.

HILCO REDEVELOPMENT PARTNERS BREAKS GROUND ON THE RENOVATION OF THREE BASKETBALL COURTS IN CHICAGO'S LITTLE VILLAGE COMMUNITY PROVIDING YOUTH SPORTS AND PROGRAMMING

Retrieved on: 
Monday, November 13, 2023
Holiday, Built environment, Meal, Lighting, Depression, HRP, Student, Chicago Public Schools, Culture, Research, LED, Exchange, Crawford Station, Shoe, Tree, Ball, LEED, Christmas, CPS, Crime, Environment, 31st Street, Nightclub, Target

CHICAGO, Nov. 13, 2023 /PRNewswire/ -- Hilco Redevelopment Partners (HRP), a Chicago-based vertically integrated real estate investment and redevelopment company that reimagines, remediates, and redevelops complex industrial sites across the United States, has partnered with local youth sports organization Beyond the Ball to break ground on the renovation of existing basketball courts used to provide year-round youth sports programming in Chicago's Little Village Community. The renovations, which will be funded by HRP, will include new pavement, striping, fence repairs, and LED lighting.

Key Points: 
  • Beyond the Ball serves all youth in Little Village with a mission of leveraging the power of sport and play to reclaim space, unite the community, and develop a culture of opportunity.
  • "We are proud to work with our partners at Beyond the Ball to help build an environment for this community and its youth to grow and thrive."
  • In my 25 years of living in the community, the lights on the basketball courts at the Gary/Ortiz campus have never worked.
  • I am so excited for our community and especially our young people to have basketball courts with a brand-new playing surface and lighting."